| 9950066 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2018-04-24 |
$202,734,000 |
| 9750808 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2017-09-05 |
$217,104,000 |
| 9738714 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2017-08-22 |
$477,835,000 |
| 9732152 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2017-08-15 |
$229,452,000 |
| 9327032 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2016-05-03 |
$240,315,000 |
| 9302011 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2016-04-05 |
$168,990,000 |
| 9295725 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2016-03-29 |
$208,660,000 |
| 9289497 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2016-03-22 |
$157,995,000 |
| 9272042 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2016-03-01 |
$121,077,000 |
| 9272041 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2016-03-01 |
$121,077,000 |
| 9220781 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2015-12-29 |
$639,385,000 |
| 9114166 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2015-08-25 |
$117,883,000 |
| 8940305 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2015-01-27 |
$84,369,000 |
| 8932591 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2015-01-13 |
$472,144,000 |
| 8916158 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-12-23 |
$118,218,000 |
| 8916157 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-12-23 |
$118,218,000 |
| 8911741 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-12-16 |
$241,698,000 |
| 8802102 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-08-12 |
$78,239,000 |
| 8802101 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-08-12 |
$78,239,000 |
| 8802100 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-08-12 |
$78,239,000 |
| 8795670 |
Formulation of human antibodies for treating TNF-alpha associated disorders |
Hans-Juergen Krause, Lisa Baust |
2014-08-05 |
$63,281,000 |
| 8216583 |
Formulation of human antibodies for treating TNF-α associated disorders |
Hans-Juergen Kruase, Lisa Baust |
2012-07-10 |
|
| 5622936 |
Tumor inhibiting saccharide conjugates |
Manfred Wiessler |
1997-04-22 |
|
